| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Outsourcing > Offshoring: Competitive Edge |
|
Advice You - Offshoring: Competitive Edge
Trends in offshoring business processes are getting stronger and more stable. From simple assembly tasks, multinational com According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product panies are now set to move their research and development tasks to countries that have met their stringent standards. A rec ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in nt study presented to the National Academies in the United States say corporations will send more and more of their researc lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. h offshore. These businesses are targeting progressive economies that hold substantial human resources adept in informatio here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe technology, engineering and the sciences. Lure of minimal set-ups and overhead on the other hand, is just an added bonus. d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ain reason for exporting such activities is still the quality of work these offshore professionals deliver. Over 38 percent ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc of the 200 multinational firms surveyed are going to decentralize their development process in the next three years. They easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi re now globally shopping for talents capable of meeting their dynamic needs. In fact, executives believe offshoring gives t nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically em the business edge they demand in their respective industries. It is no wonder outsourced activities are climbing the co and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ rporate ladder. But very few people see this as a threat to their corporate wares. Instead, it is perceived as just and nat ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ral progression of a normal booming business. Increasing awareness of info-tech gadgets also helps management monitor devel ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a pments on their investments, unburdening them of worries caused by running a portion of their business overseas. Now, busi dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod nesses operating within different industries without their own websites are considered, not only site-less but also sightle cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin s. Robert Heller, a leading management guru, went even further when he said – “the new breed of organizations must be built tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen on change, not stability: round networks, not hierarchy: on interdependencies, not self-sufficiency: on technological advan t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel tage, not fixed assets.” It seems like offshoring is being deemed as the solution for giving existing firms their competit ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ve edge. Others who do not do so, may find themselves behind league leaders in terms of market share and profits. More impo y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products tantly, offshoring provides higher returns on investment companies have seen in years. Making it not only the “hottest busi . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ness trend” around, but an “industry must” if companies and corporations are to survive and excel in their present industri elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Growing Your Business With Marketing Gifts Horticulture: Pursuing a Career in Horticulture Tips in Managing a Successful Project
|